A Phase 1a/1b Trial of Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
Latest Information Update: 06 Sep 2023
At a glance
- Drugs Sorafenib (Primary) ; Trametinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 09 Jun 2021 Status changed from active, no longer recruiting to completed.
- 04 Jan 2021 Planned End Date changed from 1 Dec 2020 to 1 Jun 2021.
- 17 Dec 2019 Planned End Date changed from 1 Apr 2020 to 1 Dec 2020.